**Tracy 1999** Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol. 1999 May;47(5):545-52. PubMed PMID: 10336579; PubMed Central PMCID: PMC2014179.

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531. doi: 10.1002/psp4.12134. Epub 2016 Oct 19. 	

**PK-Sim Ontogeny Database Version 7.3** (https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf)	

**Schlender 2016** Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, Jaehde U. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals. Clin Pharmacokinet. 2016 Dec;55(12):1573-1589. 	

**Nishimura 2003** Nishimura, M., Yaguti, H., Yoshitsugu, H., Naito, S. & Satoh, T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. J. Pharm. Soc. Japan 123, 369–75 (2003).

**Perdaems 2010** Perdaems N, Blasco H, Vinson C, Chenel M, Whalley S, Cazade F, Bouzom F. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin Pharmacokinet. 2010 Apr;49(4):239-58. doi: 10.2165/11318130-000000000-00000. PubMed PMID: 20214408.

**Sandström 1999** Sandström R, Knutson TW, Knutson L, Jansson B, Lennernäs H. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. Br J Clin Pharmacol. 1999 Aug;48(2):180-9. PubMed PMID: 10417494; PubMed Central PMCID: PMC2014302.

**Heikkinen 2012** Heikkinen AT, Baneyx G, Caruso A, Parrott N. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus. Eur J Pharm Sci. 2012 Sep 29;47(2):375-86. doi: 10.1016/j.ejps.2012.06.013. Epub 2012 Jul 1. PubMed PMID: 22759901.

**Vogelpoel 2004** Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Möller H, Olling M, Shah VP, Barends DM. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci. 2004 Aug;93(8):1945-56. PubMed PMID: 15236445.

**Barbarash 1988** Barbarash RA, Bauman JL, Fischer JH, Kondos GT, Batenhorst RL. Near-total reduction in verapamil bioavailability by rifampin. Electrocardiographic correlates. Chest. 1988 Nov;94(5):954-9. PubMed PMID: 3180898.

**Johnston 1981** Johnston A, Burgess CD, Hamer J. Systemic availability of oral verapamil and effect on PR interval in man. Br J Clin Pharmacol. 1981 Sep;12(3):397-400. PubMed PMID: 7295469; PubMed Central PMCID: PMC1401793.

**McAllister 1982** McAllister RG Jr, Kirsten EB. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther. 1982 Apr;31(4):418-26. PubMed PMID: 7060323.

**Freedman 1981** Freedman SB, Richmond DR, Ashley JJ, Kelly DT. Verapamil kinetics in normal subjects and patients with coronary artery spasm. Clin Pharmacol Ther. 1981 Nov;30(5):644-52. PubMed PMID: 7297023.

**Maeda 2011** Maeda K, Takano J, Ikeda Y, Fujita T, Oyama Y, Nozawa K, Kumagai Y, Sugiyama Y. Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. Clin Pharmacol Ther. 2011 Aug;90(2):263-70. doi: 10.1038/clpt.2011.108. Epub 2011 Jun 29. PubMed PMID: 21716273.

**Mooy 1985** Mooy J, Schols M, v Baak M, v Hooff M, Muytjens A, Rahn KH. Pharmacokinetics of verapamil in patients with renal failure. Eur J Clin Pharmacol. 1985;28(4):405-10. PubMed PMID: 4029246.

**Streit 2005** Streit M, Göggelmann C, Dehnert C, Burhenne J, Riedel KD, Menold E, Mikus G, Bärtsch P, Haefeli WE. Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). Eur J Clin Pharmacol. 2005 Mar;61(1):39-46. Epub 2005 Feb 4. PubMed PMID: 15692829.

**Hla 1987** Hla KK, Henry JA, Latham AN. Pharmacokinetics and pharmacodynamics of two formulations of verapamil. Br J Clin Pharmacol. 1987 Nov;24(5):661-4. PubMed PMID: 3435694; PubMed Central PMCID: PMC1386339.

**Joergenson 1988** Jørgensen NP, Walstad RA. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations. Pharmacol Toxicol. 1988 Aug;63(2):105-7. PubMed PMID: 3186615.

**Shand 1981** Shand DG, Hammill SC, Aanonsen L, Pritchett EL. Reduced verapamil clearance during long-term oral administration. Clin Pharmacol Ther. 1981 Nov;30(5):701-6. PubMed PMID: 7297027.

**Johnson 2001** Johnson BF, Cheng SL, Venitz J. Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic. J Clin Pharmacol. 2001 Nov;41(11):1248-56. PubMed PMID: 11697758.

**van Haarst 2009** van Haarst AD, Dijkmans AC, Weimann HJ, Kemme MJ, Bosch JJ, Schoemaker RC, Cohen AF, Burggraaf J. Clinically important interaction between tedisamil and verapamil. J Clin Pharmacol. 2009 May;49(5):560-7. doi: 10.1177/0091270009332812. Epub 2009 Mar 19. PubMed PMID: 19299533

**Karim 1995** Karim A, Piergies A. Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both. Clin Pharmacol Ther. 1995 Aug;58(2):174-84. PubMed PMID: 7648767.

**Meredith 1985** Meredith PA, Elliott HL, Pasanisi F, Kelman AW, Sumner DJ, Reid JL. Verapamil pharmacokinetics and apparent hepatic and renal blood flow. Br J Clin Pharmacol. 1985 Aug;20(2):101-6. PubMed PMID: 4041329; PubMed Central PMCID: PMC1400678.

**Rowland-Yeo 2011** Rowland Yeo K, Walsky RL, Jamei M, Rostami-Hodjegan A, Tucker GT. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur J Pharm Sci. 2011 Jun 14;43(3):160-73. doi: 10.1016/j.ejps.2011.04.008. Epub 2011 Apr 20. PubMed PMID: 21540107.